BCRX - BioCryst Pharmaceuticals Inc Stock Price, Fair Value and News

$7.37-0.25 (-3.28%)

Delayed as of 25 Nov 2024, 02:02 pm ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

BCRX Price Action

Last 7 days

8.4%

Last 30 days

-5.5%

Last 90 days

-5.9%

Trailing 12 Months

41.9%

BCRX RSI Chart

BCRX Valuation

Market Cap

1.6B

Price/Earnings (Trailing)

-12.75

Price/Sales (Trailing)

3.83

EV/EBITDA

-83.15

Price/Free Cashflow

-28.32

BCRX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

BCRX Fundamentals

BCRX Revenue

Revenue (TTM)

412.6M

Rev. Growth (Yr)

34.98%

Rev. Growth (Qtr)

7.09%

BCRX Earnings

Earnings (TTM)

-123.8M

Earnings Growth (Yr)

61.18%

Earnings Growth (Qtr)

-10.72%

BCRX Profitability

EBT Margin

-30.09%

Return on Equity

26.42%

Return on Assets

-25.2%

Free Cashflow Yield

-3.53%

BCRX Investor Care

Shares Dilution (1Y)

1.13%

Diluted EPS (TTM)

-0.61

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	355.4M	382.2M	412.6M	0
2023	289.7M	306.6M	317.6M	331.4M
2022	188.0M	203.6M	238.4M	270.8M
2021	32.0M	79.1M	114.0M	157.2M
2020	47.8M	49.2M	53.5M	17.8M
2019	22.6M	11.5M	11.8M	48.8M
2018	19.7M	29.1M	21.8M	20.7M
2017	31.0M	29.3M	30.3M	25.2M
2016	46.3M	25.2M	22.0M	26.4M
2015	17.0M	41.4M	49.1M	48.3M
2014	17.2M	17.9M	18.7M	13.6M
2013	16.2M	12.8M	12.3M	17.3M
2012	26.4M	26.9M	24.5M	24.8M
2011	41.7M	37.9M	31.1M	19.6M
2010	0	70.5M	66.5M	62.4M
2009	0	0	0	74.6M

Get all data in R, Python etc through our Historical Stock Data APIs

About BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor for complement-mediated diseases; and Galidesivir, to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

CEO	Mr. Jon P. Stonehouse
WEBSITE	biocryst.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	531

BioCryst Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for BioCryst Pharmaceuticals Inc? What does BCRX stand for in stocks?

BCRX is the stock ticker symbol of BioCryst Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of BioCryst Pharmaceuticals Inc (BCRX)?

As of Fri Nov 22 2024, market cap of BioCryst Pharmaceuticals Inc is 1.58 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BCRX stock?

You can check BCRX's fair value in chart for subscribers.

Is BioCryst Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether BCRX is over valued or under valued. Whether BioCryst Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact BioCryst Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BCRX.

What is BioCryst Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Nov 22 2024, BCRX's PE ratio (Price to Earnings) is -12.75 and Price to Sales (PS) ratio is 3.83. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BCRX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on BioCryst Pharmaceuticals Inc's stock?

In the past 10 years, BioCryst Pharmaceuticals Inc has provided -0.037 (multiply by 100 for percentage) rate of return.